首页 | 本学科首页   官方微博 | 高级检索  
检索        

Citicoline对大鼠中脑原代细胞培养的神经保护作用
引用本文:姜晓燕,贾晓晶,吕文天,赵红光,王志成,龚守良.Citicoline对大鼠中脑原代细胞培养的神经保护作用[J].吉林大学学报(医学版),2006,32(2):224-227.
作者姓名:姜晓燕  贾晓晶  吕文天  赵红光  王志成  龚守良
作者单位:1. 吉林大学公共卫生学院 卫生部放射生物学重点实验室,吉林 长春130021;2. 吉林大学第二医院放疗科,吉林 长春130041;3. 长春市卫生局卫生监督所,吉林 长春130033
基金项目:中国-奥地利科技合作项目
摘    要:目的:探讨胞二磷胆碱(citicoline,CC)对6-OHDA诱导的帕金森体外细胞模型的保护作用及其机理。方法:孕15 d大鼠胚胎中脑原代培养,在培养第6 、8及10天,实验组加不同浓度CC(2、1、0.1、0.01和0.001 mmol·L-1 ),并于第11天加50 μmol·L-1的6-OHDA作用0.5 h,制作帕金森病细胞模型;6-OHDA组为原代培养细胞加50 μmol·L-1的6-OHDA;对照组为原代培养细胞。培养11 d收集细胞。采用MTT法测细胞活力,通过流式细胞仪,用Fluo3/AM检测细胞内Ca2+i及用罗丹明123检测线粒体膜电位(Δψm)。结果:2、1和0.1 mmol·L-1 CC组,细胞活力与对照组比较明显增高,并随着浓度的增加而增加,差异具有显著性(P<0.05)。1、0.1、0.01 和0.001 mmol·L-1 CC+6-OHDA组,细胞活力均高于6-OHDA组,差异有显著性(P<0.01)。1、0.1、0.01、0.001 mmol·L-1 CC+6-OHDA组细胞内Ca2+i均明显下降,分别为(32.23±1.87)%、(17.09±7.45)%、(21.71±8.89)%及(29.18±4.71)%,与6-OHDA组(49.30±7.62)%相比,差异均有显著性(P<0.01);与对照组(42.40±0.81)%比较明显下降,差异均有显著性(P<0.01)。CC+6-OHDA各组与6-OHDA组比较均使Δψm升高,其中1 mmol·L-1CC+6-OHDA组Δψm高于对照组,差异有显著性(P<0.01)。结论:CC通过保护神经元细胞膜、增加细胞活力、降低细胞内Ca2+i以及提高Δψm,发挥其对神经元的保护作用。

关 键 词:神经元  细胞  培养的  羟多巴胺  帕金森病  神经保护药    
文章编号:1671-587X(2006)02-0224-04
收稿时间:2005-10-31
修稿时间:2005年10月31日

Neuroprotective effects of citicoline on 6-hydroxydopamine-treated mesencephalic dopaminergic neurons in primary culture
JIANG Xiao-yan,JIA Xiao-jing,LU Wen-tian,ZHAO Hong-guang,WANG Zhi-cheng,GONG Shou-liang.Neuroprotective effects of citicoline on 6-hydroxydopamine-treated mesencephalic dopaminergic neurons in primary culture[J].Journal of Jilin University: Med Ed,2006,32(2):224-227.
Authors:JIANG Xiao-yan  JIA Xiao-jing  LU Wen-tian  ZHAO Hong-guang  WANG Zhi-cheng  GONG Shou-liang
Institution:1. MH Radiobiology Research Unit, School of Public Health, Jilin University, Changchun 130021,China; 2. Department of Radiotherapy, Second Hospital, Jilin University, Changchun 130041, China; 3. Public Health Supervision Institution of Changchun City, Changchun 130033, China
Abstract:Objective To study the neuroprotective effects of citicoline(CC) on the toxicity induced by 6-OHDA towards dopaminergic mesencephalic neurons in primary culture-Parkinson′s disease(PD) model in vitro and its mechanism. Methods Mesencephalic neurons in culture were prepared from embryonic 15-day Wistar rats.Cultures were treated for 6,8,10 d with various concentrations of CC(2,1,0.1,0.01 and 0.001 mmol·L~(-1)).At 11th day,the cultures were co-treated with the toxin 6-OHDA(50 μmol·L~(-1)) for 0.5 h,the cells were collected.Seven groups were categorized as follows:CC(2,1, 0.1,0.01 and 0.001 mmol·L~(-1)) +6-OHDA,control and(6-OHDA) group.The cell viability was evaluated with MTT assay.Intracellular free Ca~(2+),Ca~(2+)]i,was labeled by using the fluorescent dye Fluo3-AM and detected by flow cytometer.By measuring the intracellular Rhodamine(123 fluorescence) density with flow cytometer,mitochondrial membrane potential(MMP) was evaluated.(Results Cultures) were treated with 2,1 and 0.1 mmol·L~(-1) CC,the viability of cell was increased(P<0.05).1,0.1,0.01 and 0.001 mmol·L~(-1) CC significantly attenuated 6-OHDA-induced neurotoxic effects.As compared with(6-OHDA,) the viability of neurons increased,the meanCa~(2+)]i was significantly lower in cells treated with CC(1,0.1,0.01 and 0.001 mmol·L~(-1)) plus 6-OHDA(49.30±7.62)% than that in 6-OHDA group without CC treatment(P<0.01).The densities of Ca~(2+)]i in CC(1,0.1,0.01 and 0.001 mmol·L~(-1)) plus 6-OHDA groups were(32.23±1.87)%,(17.09±7.45)%,(21.71±8.89)%,(29.18±4.71)%,respectively,and the density of mean Ca~(2+)]i in 6-OHDA group was(49.30±7.62)%.MMP significantly increased(P<0.01).(Conclusion CC has) an important effect on dopaminergic cell survival in vitro in a validated model of PD.The neurotoxic effect of 6-OHDA can be reduced by CC and CC can increase the viability of neurons,decrease Ca~(2+)]i,maintain MMP at a relatively higher level.
Keywords:citicoline  neurons  cells  cultured  dopamine  Parkinson′s disease  neuroprotective remedy
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《吉林大学学报(医学版)》浏览原始摘要信息
点击此处可从《吉林大学学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号